Navigation Links
ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Date:5/7/2009

study drugs, had no major violations of the inclusion/exclusion criteria and had complete pharmacokinetic data were included in the analysis.

About ANX-514 (docetaxel emulsion)

ANX-514 is a novel nano-emulsion formulation of the chemotherapy drug docetaxel, a formulation of which is marketed under the brand name Taxotere. ANX-514 is formulated without polysorbate 80 or other detergents and is intended to reduce the severity and/or incidence of hypersensitivity reactions. Docetaxel is an anti-cancer agent that acts by disrupting the cellular microtubular network that is essential for cell division. Immunosuppressant premedication is recommended for docetaxel therapy to reduce the incidence and severity of hypersensitivity reactions. Docetaxel is approved to treat breast, non-small cell lung, prostate, gastric and head and neck cancers.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company whose proprietary product candidates are designed to improve the safety and commercial potential of existing cancer treatments. In December 2008, the Company announced that it is exploring a range of strategic options, including the sale or disposition of one or more of its product candidate programs, a strategic business merger and other transactions that maximize the value of the Company's assets. In January and March 2009, the Company announced headcount reductions and cost containment measures to provide additional time to consummate a strategic transaction or otherwise obtain financing. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they ma
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
2. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
3. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
4. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
5. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
8. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
9. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
10. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Inc. (Nasdaq: BLUD ), a global leader in ... today announced that it will release its fiscal 2010 ... the market close. The Company will host a conference ... (Eastern Time) to discuss the results. ,, ... by dialing 1-888-324-9321 (Passcode: BLUD). Investors can also access ...
(Date:12/15/2009)... Robbins & Myers, Inc. (NYSE: ... for its fiscal 2010 first quarter ending November 30, ... 2010. A live webcast is scheduled for ... Peter C. Wallace, President and Chief Executive ... Financial Officer, will be discussing the Company,s performance and ...
(Date:12/15/2009)... U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic ... no, and 1 abstention that AstraZeneca has established sufficient ... use of CRESTOR® (rosuvastatin calcium) in individuals meeting the ... to 50 years, women greater than or equal to ... hsCRP greater than or equal to 2.0 mg/L; Triglycerides ...
Breaking Medicine Technology:Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 5Hamptons Artists 26 Writers 61st Annual Charity Softball Game To Benefit Phoenix House To be Held at Herrick Park East Hampton Saturday August 1 53532 1Hamptons Artists 26 Writers 61st Annual Charity Softball Game To Benefit Phoenix House To be Held at Herrick Park East Hampton Saturday August 1 53532 2Hamptons Artists 26 Writers 61st Annual Charity Softball Game To Benefit Phoenix House To be Held at Herrick Park East Hampton Saturday August 1 53532 3Boldly Going Virtual Leading Physical and Online Event Experts Present Live Video Webcast 53530 1Boldly Going Virtual Leading Physical and Online Event Experts Present Live Video Webcast 53530 2Boldly Going Virtual Leading Physical and Online Event Experts Present Live Video Webcast 53530 3Lots of Schoolkids Squint to See Chalkboard 53528 1
(Date:12/15/2009)... 800,000 doses have lower strength than needed for protection, ... Almost 800,000 children,s doses of H1N1 swine flu vaccine ... they have lost some potency, federal health officials said ... Control and Prevention, the company,s routine testing of the ... years found that four batches had lower than required ...
(Date:12/15/2009)... 15 Knowledge Networks ... pharmaceutical and bio-tech research market with the ... the past 11 years CMR has built ... Network (PCN®), which now includes 70,000 U.S. ... primary care and hard-to-reach specialties. The ...
(Date:12/15/2009)... 15 The following are the remarks ... the criminal division, at the Medicare Fraud Strike ... And thank you for the enormous effort everyone ... ,, Together, our Departments have and will ... We,ve made tremendous progress in fighting Medicare fraud ...
(Date:12/15/2009)... reduce depression and fatigue in people struggling with chronic ... from an individual,s sense of mastery over or ... certain physical goals. , The study appears in the ... arguments on fatigue being a symptom of depression," said ... at the University of Illinois and lead author of ...
(Date:12/15/2009)... call for help, experts say , , TUESDAY, Dec. 15 ... teaching children how to spot the signs of stroke ... study shows. , Emergency medical treatment within three hours ... of brain damage and lead to better recovery. , ... 515 sixth graders in Texas who were divided into ...
Breaking Medicine News(10 mins):Health News:Large Recall of Children's Swine Flu Vaccine 2Health News:Knowledge Networks Expands in Pharma Research With Acquisition of CMR 2Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 2Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 3Health News:Mastery of physical goals lessens disease-related depression and fatigue 2Health News:Boosting Kids' Stroke IQ May Save Lives 2
... Allergies and asthma affect,six times more Americans than ... America. As the fifth leading chronic disease, allergies,along ... Americans., (Photo: http://www.newscom.com/cgi-bin/prnh/20080415/NYTUFNS1 ), ... to prevent or treat,allergies and asthma," said Peggy ...
... pancreatic tumors, scientists say , , MONDAY, April 14 ... prevent colorectal cancer, and the powerful new cancer drug ... So conclude two studies presented Monday at the American ... , In the first report, researchers found that a ...
... Changes Further Position Company to Meet Strategic ... ... ), a,leading, global full-service clinical research organization, today,announced the promotion of ... had served as President and Chief Operating,Officer, will continue as Chief ...
... (Nasdaq: CVTX ) today announced that it will ... opens on Friday, April 25,2008. Company management will webcast ... on the company,s website., To access the live ... http://www.cvt.com and go to the Investor Information section. ...
... Conseco, Inc. (NYSE:,CNO) announced that Timothy S. ... risk management, reporting to Tim Tongson, senior ... responsible for overseeing and,coordinating the enterprise-wide risk ... Management Committee., At Conseco, Mr. Bischof ...
... Inc. (Nasdaq: ALXN ), today announced that the ... on Wednesday, April 30, 2008,at 10:00 a.m. Eastern Time ... for the first quarter ended March 31, 2008. Alexion,anticipates ... Wednesday,April 30, 2008., To participate in this conference ...
Other Medicine News:Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Allergies and Asthma Relief 2Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Allergies and Asthma Relief 3Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Allergies and Asthma Relief 4Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Allergies and Asthma Relief 5Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Allergies and Asthma Relief 6Health News:New Treatments Help Fight Liver, Colon Cancer 2Health News:New Treatments Help Fight Liver, Colon Cancer 3Health News:New Treatments Help Fight Liver, Colon Cancer 4Health News:Kendle Promotes Simon S. Higginbotham to President; Appoints Alan J. Boyce as Chief Marketing Officer 2Health News:Kendle Promotes Simon S. Higginbotham to President; Appoints Alan J. Boyce as Chief Marketing Officer 3Health News:CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday, April 25, 2008 2
... The GenoSensor System includes genomic ... software, and reagents. By utilizing ... (CGH) technology for multi-target assessment, ... analyze multiple genomic targets in ...
The ABI PRISM 3100 Genetic Analyzer, a multi-color fluorescence-based DNA analysis system with 16 capillaries operating in parallel, offers high-quality data and efficient sample processing for the b...
... CELL-DYN 1800 is the latest 3-part differential ... since the founding of the CELL-DYN line. ... data management capabilities, the CELL-DYN 1800 meets ... CELL-DYN 1800 is smaller than its predecessors ...
... The QC Manager Point-of-Care Data Management System ... Blood Glucose Testing System and the Precision ... simple, automated way to collect, analyze, and ... format. It provides an essential laboratory tool ...
Medicine Products: